Harrow HROW Accrued Rebates And Copay Assistance
Accrued Rebates And Copay Assistance at other companies
Other financials
Where this comes from
Reported directly by Harrow in its filing.
Tagged under the XBRL concept HROW:AccruedRebatesAndCopayAssistance.
The official record: Harrow’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Harrow's accrued rebates and copay assistance.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Harrow's accrued rebates and copay assistance?
- Harrow (HROW) reported accrued rebates and copay assistance of $51.13M in Q1 2026.
- How has Harrow's accrued rebates and copay assistance changed year-over-year?
- Harrow's accrued rebates and copay assistance increased by 64.1% year-over-year, from $31.15M to $51.13M.
- What is the long-term trend for Harrow's accrued rebates and copay assistance?
- Over 2 years (2023 to 2025), Harrow's accrued rebates and copay assistance has grown at a 51.4% compound annual growth rate (CAGR), from $18.43M to $42.24M.
- What does accrued rebates and copay assistance mean?
- This represents the estimated liability for rebates, discounts, and patient copay assistance programs owed to distributors, pharmacy benefit managers, or patients. It reflects the company's obligation to provide financial incentives or support to facilitate product access and market penetration. High levels may indicate aggressive sales growth strategies or significant reliance on patient assistance programs to drive volume.